

Ontario Public Drug Programs

Drug Submission Status
Updated: October 19, 2012

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Riluzole	Rilutek	riluzole	50mg	FC tablet	02352583
Apotex Inc.	Apo-Lamivudine HBV	Heptovir	lamivudine methanol solvate	100mg	FC tablet	02393239
Jamp Pharma Corporation	Jamp-Montelukast	Singulair	montelukast sodium	10mg	FC tablet	02391422
Marcan Pharmaceuticals Inc.	Mar-Fluoxetine	Prozac	fluoxetine hydrochloride	10mg	capsule	02392909
Patriot, A Division of Janssen Inc.	Pat-Tramadol/Acet	Tramacet	tramadol hydrochloride/acetaminophen	37.5mg/ 325mg	FC tablet	02389274

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Ranbaxy Pharmaceuticals Canada Inc.	Ran-Tramadol/ Acet	Tramacet	tramadol hydrochloride/ acetaminophen	37.5mg/ 325mg	FC tablet	02388197
Teva Canada Limited	Novo-Valacyclovir	Valtrex	valacyclovir hydrochloride	1000mg	FC tablet	02357542